-
1 Comment
Tonghua Dongbao Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 8.2% below its 200 day moving average.
From a valuation standpoint, the stock is 10.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.6.
Tonghua Dongbao Pharmaceutical Co., Ltd's total revenue sank by 1.3% to $711M since the same quarter in the previous year.
Its net income has increased by 74.1% to $214M since the same quarter in the previous year.
Finally, its free cash flow grew by 65.8% to $250M since the same quarter in the previous year.
Based on the above factors, Tonghua Dongbao Pharmaceutical Co., Ltd gets an overall score of 3/5.
| Exchange | SHG |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE000000H87 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Market Cap | 16B |
|---|---|
| PE Ratio | 13.27 |
| Target Price | 11.04 |
| Beta | 0.17 |
| Dividend Yield | 3.5% |
Tonghua Dongbao Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of biological products, traditional Chinese medicines, chemical medicines, and other drugs in China and internationally. The company offers liraglutide injections; insulin glargine injections; insulin aspart injections; human insulin injections; isophane protamine human insulin injections; mixed protamine human insulin injections; suganning capsules; pediatric paracetamol and artificial cow-bezoar and chlorphenamine maleate granules; zhennaoning capsules; compound methionine and choline bitartrate tablets; and compound kushen changyankang tablets. It also provides insulin pens and pen needles; and the Chronic Disease Management Platform, which is a diabetes management platform for drug treatment, blood glucose monitoring, and patient education. In addition, the company offers oral anti-diabetic hypoglycemic drugs, such as sitagliptin phosphate, sitagliptin phosphate/metformin hydrochloride, repaglinide, and engagliflozin tablets. Further, it engages in the manufacture, sale, and servicing of plastic building materials and products; technology development of biological products and natural medicines; leasing of workshops; real estate development and sales; second-hand housing transactions; provision of biopharmaceuticals; medical research and experimental development; pharmaceutical retail and wholesale; technical services, technology development, and technical consulting; operation of medical devices and food products; import and export of goods and technologies; internet sales; and health and consulting services. Tonghua Dongbao Pharmaceutical Co., Ltd. was founded in 1985 and is headquartered in Tonghua, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 600867.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
